<DOC>
	<DOC>NCT00686920</DOC>
	<brief_summary>This study will look at the safety of a drug used in patients who have had hepatic encephalopathy in the past.</brief_summary>
	<brief_title>Safety Study for Patients With a History of Hepatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<criteria>Must sign an Informed Consent Form In remission from past hepatic encephalopathy (HE). Appropriate birth control measures More than or equal to 18 years of age. Must be potential for benefit from treatment. Recent HE episodes Capable and willing to comply with all study procedures. Subject has support network. Significant medical conditions or Investigator decision not to include. Allergies to the study drug or similar drugs. Laboratory abnormalities. Recent participation in another clinical trial Problems experienced in a previous HE trial. Pregnant or at risk of pregnancy. Recent alcohol consumption Active or latent bacterial or viral Infections Bowel issues Recent Active Cancer On a prohibited medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>